Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Irritable Bowel Syndrome With Constipation (IBS-C): full-pipeline trial registry
2 of 2 indexed Irritable Bowel Syndrome With Constipation (IBS-C) trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Irritable Bowel Syndrome With Constipation (IBS-C): 2 US clinical trials tracked, 2 recruiting.
Irritable Bowel Syndrome With Constipation (IBS-C) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Ardelyx, running 2 of these trials.
Enrollment posture brief
Registry condition irritable-bowel-syndrome-with-constipation-ibs-c
OPEN 2 | RECR 100% | LATE 1 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Irritable Bowel Syndrome With Constipation (IBS-C) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Irritable Bowel Syndrome With Constipation (IBS-C) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Irritable Bowel Syndrome With Constipation (IBS-C) is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Ardelyx
NCT05643534
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
Ardelyx
NCT06553547
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Irritable Bowel Syndrome With Constipation (IBS-C) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Irritable Bowel Syndrome With Constipation (IBS-C) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Irritable Bowel Syndrome With Constipation (IBS-C) page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Irritable Bowel Syndrome With Constipation (IBS-C) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ardelyx sponsors the most Irritable Bowel Syndrome With Constipation (IBS-C) trials on record, review their full trial history before evaluating a specific study. See Ardelyx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Irritable Bowel Syndrome With Constipation (IBS-C) condition card totals 2 registered trials; most-linked intervention Placebo; top US site state Nebraska. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.